LIMFLOW SA
LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.
LIMFLOW SA
Industry:
Emergency Medicine Health Care Medical Device
Founded:
2012-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.limflow.com
Total Employee:
11+
Status:
Active
Contact:
+33.638.747.190
Email Addresses:
[email protected]
Total Funding:
63 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
AventaMed
AventaMed is an emerging medical device company
Consure Medical
Consure Medical is an emerging medical device company.
FineHeart
FineHeart is a medical device company
Kumovis
Kumovis is a medical technology Company.
Medtrum
Medtrum is a diabetes management medical device developer.
Minerva Surgical
Minerva Surgical is a medical device start-up company developing medical devices for women’s healthcare.
P3 Health Partners
P3 Health Partners is a patient-centered, physician-led and population health-focused healthcare company.
Portal Instruments
Portal Instruments is an early stage company that offers medical device.
SyMap Medical
SyMap Medical is an innovative medical device company.
ZSX Medical
ZSX Medical, LLC, is a pre-clinical stage medical device company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Soleus Capital
Soleus Capital investment in Series D - LimFlow SA
Sofinnova Partners
Sofinnova Partners investment in Series D - LimFlow SA
Bpifrance
Bpifrance investment in Series D - LimFlow SA
Balestier
Balestier investment in Series D - LimFlow SA
Longitude Capital
Longitude Capital investment in Series D - LimFlow SA
French sovereign investment bank
French sovereign investment bank investment in Series C - LimFlow SA
Bpifrance
Bpifrance investment in Series C - LimFlow SA
Balestier
Balestier investment in Series C - LimFlow SA
Sofinnova Partners
Sofinnova Partners investment in Series C - LimFlow SA
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-23 | LimFlow Appoints Jenny Gaffney as Vice President, Health Economics and Reimbursement |
Official Site Inspections
http://www.limflow.com
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "LimFlow SA"
Designed to Heal Wounds and Prevent Amputation - LimFlow
In a minimally-invasive fashion, the LimFlow System is designed to bypass blocked arteries in the leg and rush blood back into the foot, potentially avoiding major amputation, resolving pain and …See details»
LimFlow Procedure — Giving No-Hope Patients New Hope
When all CLTI treatment options have been exhausted, the LimFlow procedure is designed to restore blood flow to the ischemic foot.See details»
Inari Medical Closes Acquisition of LimFlow | Inari Medical, Inc.
Nov 15, 2023 · On November 1, Inari announced a definitive agreement to acquire LimFlow, S.A. for a total upfront consideration of $250 million paid in cash upon closing.See details»
LimFlow Products and System Overview - LimFlow
The LimFlow system consists of a family of fully percutaneous products designed to optimize perfusion of the critically ischemic foot by facilitating revascularization of the pedal arch. LimFlow is the only purpose-built system for artery to vein …See details»
LimFlow SA - Crunchbase Company Profile & Funding
LimFlow SA is a venture-backed medical device company. LimFlow SA may be growing as evidenced by a series of strategic developments. The company has been acquired by Inari …See details»
Inari Medical Completes Acquisition of LimFlow
Nov 15, 2023 · On November 1, Inari announced a definitive agreement to acquire LimFlow for a total upfront consideration of $250 million paid in cash upon closing. Contingent consideration …See details»
FDA Approves LimFlow System in Patients With …
Sep 12, 2023 · The LimFlow System is designed to reestablish blood flow in deep veins for "no-option" patients with Chronic Limb-Threatening Ischemia (CLTI). The technology bypasses permanently blocked arteries...See details»
FDA Approves Blood Flow-Diverting LimFlow System for No …
Sep 12, 2023 · The US Food and Drug Administration has approved the LimFlow self-expanding covered stent system for arterialization of deep veins in the foot in no-option patients with …See details»
LimFlow - Radcliffe Vascular
The novel LimFlow System employs a variety of proprietary technologies – including ultrasound catheters, a push valvulotome, and crossing and extension stents – to create a new and …See details»
FDA approves Limflow System in patients with chronic …
Sep 12, 2023 · The LimFlow System is indicated for patients who have chronic limb-threatening ischemia (CLTI) with no suitable endovascular or surgical revascularization options and are at risk of major amputation. The LimFlow …See details»
LimFlow — A Fully Percutaneous Procedure - LimFlow
The novel LimFlow System employs a variety of proprietary technologies — including ultrasound catheters, a push valvulotome, and crossing and extension stents — to create a new and minimally-invasive option for “no option” CLTI …See details»
LimFlow System Approved by FDA for Treatment of Patients With …
Sep 12, 2023 · The LimFlow system is designed for transcatheter arterialization of deep veins to reestablish blood flow. The LimFlow system received the CE Mark and is available …See details»
Amputations Still Avoided With Flow-Diverting Therapy for CLTI at …
Nov 6, 2024 · The US Food and Drug Administration approved the LimFlow device in 2023 on the basis of 6-month data from PROMISE II, making it the only device of its kind for transcatheter …See details»
Blood-clot buster Inari snatches up limb-saving implant maker …
Nov 2, 2023 · Inari Medical has signed on to a $415 million deal to acquire LimFlow, just weeks after the company received an FDA approval for its minimally invasive approach to re …See details»
UH Harrington Leads Pivotal Study of LimFlow Therapy for Chronic …
Jun 22, 2023 · New research from University Hospitals Harrington Heart & Vascular Institute shows that there may finally be a viable alternative to amputation for patients suffering from …See details»
A new procedure offers hope to ‘no option ... - CNN International
Mar 29, 2023 · LimFlow is a minimally invasive technique that can help people with the extreme form of peripheral artery disease called chronic limb-threatening ischemia, or CLTI.See details»
LimFlow Avoids Vessel Trauma - LimFlow
LimFlow is a minimally-invasive technology designed to divert blood around diseased arteries in the leg and into the tibial veins that feed the foot, bringing blood and oxygen to starved tissues …See details»
PROMISE I: Early feasibility study of the LimFlow System for ...
Objective: We report the 6- and 12-month outcomes of the PROMISE I early feasibility study after treatment of no-option chronic limb-threatening ischemia (CLTI) with percutaneous deep vein …See details»
PROMISE I: Early feasibility study of the LimFlow System for ...
Mar 30, 2020 · We report the 6- and 12-month outcomes of the PROMISE I early feasibility study after treatment of no-option chronic limb-threatening ischemia (CLTI) with percutaneous deep …See details»
LimFlow Percutaneous Deep Venous Arterialization
Having access to the LimFlow System has given me a new option to offer my no-option patients. TECHNICAL EXPERTISE. Performing DVA with the LimFlow System utilizes standard …See details»